Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the Headache Impact Questionnaire
Launched by GAZI UNIVERSITY · Feb 19, 2021
Trial Information
Current as of May 11, 2025
Completed
Keywords
ClinConnect Summary
The episodic nature of migraine attacks presents a number of difficulties in characterizing disease severity. There are differences in the severity, frequency and intensity of attacks and the general effect of the disease in individuals. Information about any particular attack is not sufficient to characterize the overall severity of the disease. Accordingly, the Headache Impact Questionnaire (HIQ) was developed to evaluate the headache experience over a period of time instead of any headache. Developed to measure the impact and quality of life of individuals suffering from headache, hıq ev...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with any type of headache,
- • Have a chronic headache.
- Exclusion Criteria:
- • Having a cognitive and neurological disorders.
About Gazi University
Gazi University, a leading research institution based in Ankara, Turkey, is committed to advancing medical knowledge and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university integrates cutting-edge research with clinical practice to explore new therapeutic approaches and enhance existing treatments. Gazi University adheres to the highest ethical standards and regulatory guidelines, ensuring the integrity and safety of its clinical trials. By fostering partnerships with healthcare professionals and academic institutions, Gazi University aims to contribute significantly to the global scientific community and address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, None Selected, Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials